Company

The Radiopharmaceutical industry leader in Korea
A fast growing biotech company with proven records

History

  • 2012 04. Acquired CICO Healthcare (Diagnostic Reagent Distributor)
  • 2011 02. Established a Radiopharmaceutical manufacturing facility in Chilgok-Kyungpook National University Hospital
  • 2010 11. Acquired Radiopharmaceutical manufacturing facilities (Incheon St. Mary’s Hospital, Daejeon Eulji Hospital) from DK Medical Systems Co.
    05. Established a Radiopharmaceutical production facility in Hanyang University Medical Center
  • 2009 09. Acquired a Radiopharmaceutical manufacturing facility in Kangwon National University Hospital
  • 2007 12. Company name changed from Med.ic.boss to DuChemBio
  • 2002 11. Established Med.ic.boss (Health functional food distribution company)
  • 2020 12. Execution of Licensing & Collaboration Agreement with Telix Pharmaceuticals for Ga68-PSMA-11 Prostate Cancer tracer
    07. Memocare™ Launched (Health Functional Food for cognitive function improvement)
    05. GMP renewal certification: Radiopharmaceutical production facility at Hanyang University Hospital
    04. Relocation of Corporate Headquarters(New address: 81, Wausan-ro, Mapo-gu, Seoul, Republic of Korea )
    03. GMP renewal certification: Radiopharmaceutical production facility at Sinchon Severance Hospital
  • 2019 12. Licensing-out agreement for FP-CIT with DC/AMS (China, Hongkong, Macao)
    10. Acquring approval of F-DOPA with the world’s first neutralization technology
    08. Exclusive licensing agreement for domestic development and commercialization of Solucin with Isotope Technologies Munich (ITM, Germany)
    07. GMP renewal certification: Radiopharmaceutical production facility in Chilgok-Kyungpook National University Hospital
    07. Exclusive licensing agreement with Life Molecular Imaging (LMI, Germany) for the manufacturing & supply of Neuraceq in the Philippines
    07. Signed a manufacturing agreement with KHealth (DuchemBio subsidiary in the Philippines) for FP-CIT, FES and F-DOPA
    06. Exclusive licensing agreement for the domestic development and commercialization of FACBC for Prostate cancer diagnosis with Nihon Medi Physics (NMP, Japan)
  • 2018 12. Successful ‘Technology Evaluation’ for KOSDAQ listing
    10. Received Korean National Award from Ministry of Trade, Industry and Energy for FP-CIT technology
    07. FES licensing agreement with Asan Medical Center
    01. M&A with Radiopharmaceutical Business Department of Nambuk Medical Appliance. (Acquisition of Radiopharmaceutical and business rights in Gangnam Severance, Daejeon St. Mary's Hospital)
  • 2017 12. GMP certification: Radiopharmaceutical production facility in Hanyang University Medical Center
    11. Signed a manufacturing technology licensing agreement of Bombesin diagnostic & therapeutic agents for prostate cancer with Korea Atomic Energy Research Institute (KAERI)
    09. GMP certification: Radiopharmaceutical production facility in Sinchon Severance Hospital
    08. Won the ‘New Technology Award of the Month’ by Ministry of Trade, Industry & Energy (Development of Manufacturing Technology / Cassette for FP-CIT Overseas Export)
    06. Conclusion of exclusive licensing agreement with Cerecin (former Accera) for a medical food for improvement of cognitive function
    06. World's first licensing-out agreement for FP-CIT with Cyclotek (Australia, New Zealand)
  • 2016 12. Signed a FP-CIT sub-licensing agreement with LMI (former Piramal) (DuChembio owns all FP-CIT license & rights for export)
    07. GMP certification: Radiopharmaceutical production facility in Chilgok-Kyungpook National University Hospital
    07. FP-CIT licensing agreement with Asan Medical Center (Acquiring patent rights for FP-CIT licensing)
    06. CICO Healthcare signed agreement to transfer F-DOPA patent ownership from Asan Medical Center (World’s first neutralization technology)
  • 2014 12. Listed on the KONEX (Korea New Exchange) stock market
    12. Established DuChemBio Research Institute, a joint research center with Korea Atomic Energy Research Institute
    11. NDA approval in Korea: Neuraceq, dementia diagnostic agent
  • 2013 11. Conclusion of an exclusive licensing agreement with LMI (former Piramal) for the development & commercialization of Neuraceq in Korea
    10. Korea-Spain joint research (~ October, 2016) (R&D of FP-CIT & FES cassettes for export)
    06. Launched Radiopharmaceutical business in NKTI Hospital, Manila, Philippines (1st commercial production of radiopharmaceuticals in the Philippines)
    05. Established a Radiopharmaceutical production facility in Sinchon Severance Hospital
  • 2021 09. FACBC(18F-Fluciclovine) NDA Approval
    09. DuChemBio Co.,LTD.-Carecamp Inc. merger after corporate division(Spin-Off)
    08. F-DOPA(Fluorodopa) submission of application for reimbursement to Health Insurance Review & Assessment Service
    08. Execution of Manufacturing Services Agreement with Cerveau Technologies for MK-6240 Tau Tracer
    08. Execution of Material Transfer and Clinical Supply Agreement with Life Molecular Imaging for PI 2620 Tau Tracer
    06. Memorandum of Understanding for establishment and operation of radiopharmaceutical manufacturing facility in Uzbekistan
    05. Ga68 Generator import and sale approval from Korea Institute of Nuclear Safety

그누보드5
Address 6,7F, 81, Wausan-ro, Mapo-gu, Seoul, Republic of Korea [04041]
Tel 02 332 4868 Fax 02 323 3437

Copyright © 2021, DuchemBio, Co., Ltd. All Rights Reserved